AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 7 - (NewsRx.com & NewsRx.net) -- Cypress Bioscience, Inc., (CYPB) expects its partner, Forest Laboratories (FRX) to initiate the second phase III trial evaluating milnacipran for the treatment of fibromyalgia syndrome (FMS) during the fourth quarter of this year.
Cypress is currently running the first phase III trial for milnacipran, which was commenced in October 2003. Enrollment in this trial is expected to be completed by the end of the year, with results available in the third quarter of 2005. As originally agreed, Forest Laboratories would run the second phase III clinical trial for milnacipran, with the assistance of Cypress.
In light of the increased expense and risk associated with running 2 parallel trials, Cypress and Forest are discussing an arrangement whereby, for this trial only, Cypress would initially share in some of the costs of the trial, with Forest reimbursing ...
Source: HighBeam Research, Companies to commence second phase III trial for milnacipran in Q4.